Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 14;110(9):1664-71.
doi: 10.1017/S0007114513000949. Epub 2013 Apr 3.

n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis

Affiliations

n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis

Brian T Steffen et al. Br J Nutr. .

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an independent risk factor for CVD and has been proposed as a marker of vascular inflammation. Polyunsaturated n-3 fatty acids (FA) and several n-6 FA are known to suppress inflammation and may influence Lp-PLA2 mass and activity. The associations of n-3 and n-6 plasma FA with Lp-PLA2 mass and activity were analysed using linear regression analysis in 2246 participants of the Multi-Ethnic Study of Atherosclerosis; statistical adjustments were made to control for body mass, inflammation, lipids, diabetes, and additional clinical and demographic factors. Lp-PLA2 mass and activity were significantly lower in participants with the higher n-3 FA EPA (β = - 4·72, P< 0·001; β = - 1·53; P= 0·023) and DHA levels (β = - 4·47, β = - 1·87; both P< 0·001). Those in the highest quintiles of plasma EPA and DHA showed 12·71 and 19·15 ng/ml lower Lp-PLA2 mass and 5·7 and 8·90 nmol/min per ml lower Lp-PLA2 activity than those in the first quintiles, respectively. In addition, lower Lp-PLA2 mass and activity were associated with higher levels of n-6 arachidonic acid (β = - 1·63, β = - 1·30; both P< 0·001), while γ-linolenic acid was negatively associated with activity (β = - 27·7, P= 0·027). Lp-PLA2 mass was significantly higher in participants with greater plasma levels of n-6 linoleic (β = 0·828, P= 0·011) and dihomo-γ-linolenic acids (β = 4·17, P= 0·002). Based on their independent associations with Lp-PLA2 mass and activity, certain n-3 and n-6 FA may have additional influences on CVD risk. Intervention studies are warranted to assess whether these macronutrients may directly influence Lp-PLA2 expression or activity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) (a) mass and (b) activity are shown by quintiles of plasma arachidonic acid (■) and linoleic acid (formula image). Values are means, with their standard errors represented by vertical bars. Values were adjusted for age, sex, race, education, field centre, smoking, alcohol, BMI, HDL-cholesterol, LDL-cholesterol, TAG, high-sensitivity C-reactive protein and use of statins, fibrates and aspirin. * Mean values were significantly different from those of quintile 1 (P<0·05).
Fig. 2
Fig. 2
Mean levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) (a) mass and (b) activity are shown by quintiles of plasma EPA and DHA. Values are means, with their standard errors represented by vertical bars. Values were adjusted for age, sex, race, education, field centre, smoking, alcohol, BMI, HDL-cholesterol, LDL-cholesterol, TAG, high-sensitivity C-reactive protein and use of statins, fibrates and aspirin. * Mean values were significantly different from those of quintile 1 (P<0·05).

References

    1. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;338:479–487. - PMC - PubMed
    1. Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. Vasc Health Risk Manag. 2006;2:153–156. - PMC - PubMed
    1. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small dense LDL particles in human plasma. Clin Chem. 2005;51:2264–2273. - PubMed
    1. Serruys PW, García-García HM, Buszman P, et al. Integrated biomarker and imaging study-2 investigators. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172–1182. - PubMed
    1. Jenny NS, Solomon C, Cushman M, et al. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis. 2010;209:528–532. - PMC - PubMed

Publication types